• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

HIMS stock crashes 25% on Friday after this key FDA update

by February 22, 2025
by February 22, 2025

Shares of Hims & Hers Health plunged a massive 25% on Friday to hit an intraday low of around $49.01.

The massive crash came after the US Food and Drug Administration (FDA) announced the end of the shortage of Novo Nordisk’s weight-loss drugs.

Despite this setback, HIMS stock had surged 43% in the past five days leading up to the FDA’s announcement, making today’s sharp drop a reversal of those recent gains.

HIMS stock was down around 21% to trade at $52.25 at the time of writing.

Novo Nordisk shortage problems resolve

The decision is expected to impact the availability of cheaper, compounded versions of Ozempic and Wegovy that telehealth companies like Hims & Hers Health have been offering.

The resolution could limit how telehealth programs provide cheaper compounded versions of weight-loss and diabetes drugs, coming two months after regulators stated there was no shortage of Eli Lilly’s treatments.

Compounded drugs—custom formulations made by mixing or altering ingredients—have surged in demand in the US due to tight supplies of blockbuster medications from Novo Nordisk and Eli Lilly.

Regulations permit compounding pharmacies to replicate brand-name drugs only when shortages exist and prohibit them from producing these drugs “regularly or in inordinate amounts.”

Companies such as Hims & Hers offer compounded semaglutide, the active ingredient in Ozempic and Wegovy.

While pharmacies may still create alternative formulations by adjusting doses or modifying ingredients, the decision is a setback for companies like Hims & Hers Health, which had benefited from offering these compounded versions.

Recent acquisitions from Hims and Hers

In separate news, the company today announced the acquisition of a US-based peptide facility in California, further verticalizing its long-term ability to deliver personalized medications.

The acquisition aims to enhance supply chain durability and meet the rising demand for personalized healthcare solutions in the US.

This move follows the company’s previous acquisitions of 503A and 503B facilities, reinforcing its domestic manufacturing capabilities and improving oversight on cost, availability, and quality.

Additionally, the peptide innovation capabilities from this acquisition will allow Hims & Hers to explore preventive health, metabolic optimization, cognitive performance, and recovery science in the coming years.

Earlier in the week, Hims & Hers Health announced the acquisition of Trybe Labs, a New Jersey-based at-home lab testing facility, further expanding its diagnostic and personalized healthcare capabilities.

The acquisition will enable Hims & Hers to offer at-home blood draws and more comprehensive pretreatment testing, providing an alternative to established blood-drawing services like Labcorp and Quest Diagnostics.

While financial terms were not disclosed, the company stated that the deal was funded through cash on hand.

The acquisition will enhance testing capabilities for LDL cholesterol, lipoprotein(a), cholesterol, and apolipoprotein.

It will also support expanded care access for conditions such as low testosterone, perimenopausal and menopausal support.

The post HIMS stock crashes 25% on Friday after this key FDA update appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Why Coca-Cola says DEI is essential for business success
next post
Dow, S&P 500 slide as volatile week nears end: Celsius soars, UNH stock crashes

Related Posts

Asia markets open: Nikkei hits 51,000 for the...

October 29, 2025

Morning brief: AWS’s $5B South Korea plan; Trump...

October 29, 2025

US retail power prices soar: data centers and...

October 29, 2025

China resumes US soybean imports as trade deal...

October 29, 2025

Amazon’s AWS to fuel South Korea’s AI hub...

October 29, 2025

Visa expands stablecoin network across four blockchains

October 29, 2025

US–China trade talks shift focus to AI chips,...

October 29, 2025

Europe markets open: Stocks flat as Fed looms;...

October 29, 2025

Banijay to acquire majority stake in Tipico creating...

October 28, 2025

Cathie Wood warns investors to brace for correction,...

October 28, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • Cowboy Diplomacy: Ranchers Reject Tariff Rhetoric

    October 29, 2025
  • We Have Never Been Austere

    October 29, 2025
  • Asia markets open: Nikkei hits 51,000 for the first time; Sensex jumps 100 points

    October 29, 2025
  • Morning brief: AWS’s $5B South Korea plan; Trump on Kim meet; Oil steady

    October 29, 2025
  • US retail power prices soar: data centers and supply constraints drive up costs

    October 29, 2025
  • China resumes US soybean imports as trade deal nears final stage

    October 29, 2025

Editors’ Picks

  • 1

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 2

    Pop Mart reports 188% profit surge, plans aggressive global expansion

    March 26, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 5

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 6

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 7

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025

Categories

  • Economy (3,045)
  • Editor's Pick (297)
  • Investing (185)
  • Stock (2,072)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Here’s why the Rheinmetall share price will...

August 5, 2025

Here’s why the QQQ ETF, which tracks...

May 14, 2025

Coca-Cola to buy majority stake in African...

October 21, 2025